• Oryzon Genomics’ net loss more than doubled year over year to EUR 2.62 million in the first nine months of 2026.
• R&D investment rose 71% to EUR 14.1 million, while available cash and financial investments totaled EUR 19.1 million at September-end.
• The Phase Ib ALICE-2 leukemia trial achieved a 95% overall response rate; updated results are scheduled for presentation at ASH in December.
• Management targets starting the Phase III ALICE-3 trial in 2027, subject to regulatory agreement and sufficient funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.